Cargando…

Protocol of a randomised controlled trial of real-time continuous glucose monitoring in neonatal intensive care ‘REACT’

INTRODUCTION: Hyperglycaemia is common in the very preterm infant and has been associated with adverse outcomes. Preventing hyperglycaemia without increasing the risk of hypoglycaemia has proved challenging. The development of real-time continuous glucose monitors (CGM) to inform treatment decisions...

Descripción completa

Detalles Bibliográficos
Autores principales: Beardsall, Kathryn, Thomson, Lynn, Guy, Catherine, van Weissenbruch, Mirjam M, Iglesias, Isabel, Muthukumar, Priya, Somisetty, Sateesh Kumar, Bond, Simon, Petrou, Stavros, Dunger, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988133/
https://www.ncbi.nlm.nih.gov/pubmed/29866729
http://dx.doi.org/10.1136/bmjopen-2017-020816
_version_ 1783329237625733120
author Beardsall, Kathryn
Thomson, Lynn
Guy, Catherine
van Weissenbruch, Mirjam M
Iglesias, Isabel
Muthukumar, Priya
Somisetty, Sateesh Kumar
Bond, Simon
Petrou, Stavros
Dunger, David
author_facet Beardsall, Kathryn
Thomson, Lynn
Guy, Catherine
van Weissenbruch, Mirjam M
Iglesias, Isabel
Muthukumar, Priya
Somisetty, Sateesh Kumar
Bond, Simon
Petrou, Stavros
Dunger, David
author_sort Beardsall, Kathryn
collection PubMed
description INTRODUCTION: Hyperglycaemia is common in the very preterm infant and has been associated with adverse outcomes. Preventing hyperglycaemia without increasing the risk of hypoglycaemia has proved challenging. The development of real-time continuous glucose monitors (CGM) to inform treatment decisions provides an opportunity to reduce this risk. This study aims to assess the feasibility of CGM combined with a specifically designed paper guideline to target glucose control in the preterm infant. METHODS AND ANALYSES: The Real Time Continuous Glucose Monitoring in Neonatal Intensive Care (REACT) trial is an international multicentre randomised controlled trial. 200 preterm infants ≤1200 g and ≤24 hours of age will be randomly allocated to either real-time CGM or standard care (with blinded CGM data collection). The primary outcome is time in target 2.6–10 mmol/L during the study intervention assessed using CGM. Secondary outcomes include efficacy relating to glucose control, utility including staff acceptability, safety outcomes relating to incidence and prevalence of hypoglycaemia and health economic analyses. ETHICS AND DISSEMINATION: The REACT trial has been approved by the National Health Service Health Research Authority National Research Ethics Service Committee East of England (Cambridge Central); Medical Ethics Review Committee, VU University Medical Centre, Amsterdam, The Netherlands and the Research Ethics Committee, Sant Joan de Déu Research Foundation, Barcelona, Spain. Recruitment began in July 2016 and will continue until mid-2018. The trial has been adopted by the National Institute of Health Research Clinical Research Network portfolio (ID: 18826) and is registered with anInternational Standard Randomised Control Number (ISRCTN registry ID: 12793535). Dissemination plans include presentations at scientific conferences, scientific publications and efforts at stakeholder engagement. TRIAL REGISTRATION NUMBER: ISRCTN12793535; Pre-results.
format Online
Article
Text
id pubmed-5988133
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-59881332018-06-07 Protocol of a randomised controlled trial of real-time continuous glucose monitoring in neonatal intensive care ‘REACT’ Beardsall, Kathryn Thomson, Lynn Guy, Catherine van Weissenbruch, Mirjam M Iglesias, Isabel Muthukumar, Priya Somisetty, Sateesh Kumar Bond, Simon Petrou, Stavros Dunger, David BMJ Open Paediatrics INTRODUCTION: Hyperglycaemia is common in the very preterm infant and has been associated with adverse outcomes. Preventing hyperglycaemia without increasing the risk of hypoglycaemia has proved challenging. The development of real-time continuous glucose monitors (CGM) to inform treatment decisions provides an opportunity to reduce this risk. This study aims to assess the feasibility of CGM combined with a specifically designed paper guideline to target glucose control in the preterm infant. METHODS AND ANALYSES: The Real Time Continuous Glucose Monitoring in Neonatal Intensive Care (REACT) trial is an international multicentre randomised controlled trial. 200 preterm infants ≤1200 g and ≤24 hours of age will be randomly allocated to either real-time CGM or standard care (with blinded CGM data collection). The primary outcome is time in target 2.6–10 mmol/L during the study intervention assessed using CGM. Secondary outcomes include efficacy relating to glucose control, utility including staff acceptability, safety outcomes relating to incidence and prevalence of hypoglycaemia and health economic analyses. ETHICS AND DISSEMINATION: The REACT trial has been approved by the National Health Service Health Research Authority National Research Ethics Service Committee East of England (Cambridge Central); Medical Ethics Review Committee, VU University Medical Centre, Amsterdam, The Netherlands and the Research Ethics Committee, Sant Joan de Déu Research Foundation, Barcelona, Spain. Recruitment began in July 2016 and will continue until mid-2018. The trial has been adopted by the National Institute of Health Research Clinical Research Network portfolio (ID: 18826) and is registered with anInternational Standard Randomised Control Number (ISRCTN registry ID: 12793535). Dissemination plans include presentations at scientific conferences, scientific publications and efforts at stakeholder engagement. TRIAL REGISTRATION NUMBER: ISRCTN12793535; Pre-results. BMJ Publishing Group 2018-06-04 /pmc/articles/PMC5988133/ /pubmed/29866729 http://dx.doi.org/10.1136/bmjopen-2017-020816 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/
spellingShingle Paediatrics
Beardsall, Kathryn
Thomson, Lynn
Guy, Catherine
van Weissenbruch, Mirjam M
Iglesias, Isabel
Muthukumar, Priya
Somisetty, Sateesh Kumar
Bond, Simon
Petrou, Stavros
Dunger, David
Protocol of a randomised controlled trial of real-time continuous glucose monitoring in neonatal intensive care ‘REACT’
title Protocol of a randomised controlled trial of real-time continuous glucose monitoring in neonatal intensive care ‘REACT’
title_full Protocol of a randomised controlled trial of real-time continuous glucose monitoring in neonatal intensive care ‘REACT’
title_fullStr Protocol of a randomised controlled trial of real-time continuous glucose monitoring in neonatal intensive care ‘REACT’
title_full_unstemmed Protocol of a randomised controlled trial of real-time continuous glucose monitoring in neonatal intensive care ‘REACT’
title_short Protocol of a randomised controlled trial of real-time continuous glucose monitoring in neonatal intensive care ‘REACT’
title_sort protocol of a randomised controlled trial of real-time continuous glucose monitoring in neonatal intensive care ‘react’
topic Paediatrics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988133/
https://www.ncbi.nlm.nih.gov/pubmed/29866729
http://dx.doi.org/10.1136/bmjopen-2017-020816
work_keys_str_mv AT beardsallkathryn protocolofarandomisedcontrolledtrialofrealtimecontinuousglucosemonitoringinneonatalintensivecarereact
AT thomsonlynn protocolofarandomisedcontrolledtrialofrealtimecontinuousglucosemonitoringinneonatalintensivecarereact
AT guycatherine protocolofarandomisedcontrolledtrialofrealtimecontinuousglucosemonitoringinneonatalintensivecarereact
AT vanweissenbruchmirjamm protocolofarandomisedcontrolledtrialofrealtimecontinuousglucosemonitoringinneonatalintensivecarereact
AT iglesiasisabel protocolofarandomisedcontrolledtrialofrealtimecontinuousglucosemonitoringinneonatalintensivecarereact
AT muthukumarpriya protocolofarandomisedcontrolledtrialofrealtimecontinuousglucosemonitoringinneonatalintensivecarereact
AT somisettysateeshkumar protocolofarandomisedcontrolledtrialofrealtimecontinuousglucosemonitoringinneonatalintensivecarereact
AT bondsimon protocolofarandomisedcontrolledtrialofrealtimecontinuousglucosemonitoringinneonatalintensivecarereact
AT petroustavros protocolofarandomisedcontrolledtrialofrealtimecontinuousglucosemonitoringinneonatalintensivecarereact
AT dungerdavid protocolofarandomisedcontrolledtrialofrealtimecontinuousglucosemonitoringinneonatalintensivecarereact
AT protocolofarandomisedcontrolledtrialofrealtimecontinuousglucosemonitoringinneonatalintensivecarereact